Semiquantitative Analysis of Apolipoprotein A-I Modified by Advanced Glycation End Products in Diabetes Mellitus

Journal of Clinical Laboratory Analysis

Volumn 27, Issue 3, 2013, Pages 231-236

  Kurosaki, Yoshifumi ^a   Tsukushi, Tomoaki ^b   Munekata, Shinichi ^b   Akahoshi, Tohru ^c   Moriya, Tatsumi ^c   Ogawa, Zensuke ^a  

^a KITASATO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY HOSPITAL   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced glycation end products; Apolipoprotein A I; Diabetes mellitus; Enzyme linked immunosorbent assay; HDL cholesterol

Indexed keywords

ADVANCED GLYCATION END PRODUCT; APOLIPOPROTEIN A1; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MALE; PROTEIN ANALYSIS; PROTEIN MODIFICATION; QUANTITATIVE ANALYSIS;

AGED; ANALYSIS OF VARIANCE; APOLIPOPROTEIN A-I; CASE-CONTROL STUDIES; DIABETES MELLITUS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC;

EID: 84878060423     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21591     Document Type: Article

References (24)

1. Koening RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus. N Eng J Med 1976;295:417-420.
2. van Boekel MA. The role of glycation in aging and diabetes mellitus. Mol Biol Rep 1991;15:57-64.
3. Lo TW, Westwood ME, McLellan AC, Selwood T, Thornalley PJ. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha- acetylarginine, N alpha-acetylcysteine, and N alpha acetyllysine, and bovine serum albumin. J Biol Chem 1994;269:32299-32305.
4. Bruno I, Graciela C, Veronique C, et al. In vivo glucosylated LpA-I subfraction. Arterioscler Thromb Vasc Biol 1997;17:2830-2836.
5. Gantman A, Fuhrman B, Aviram M, Hayek T. High glucose stimulates macrophage SR-BI expression and induces a switch in its activity from cholesterol efflux to cholesterol influx. Biochem Biophys Res Commun 2010;391:523-528.
6. Nobecourt E, Davies MJ, Brown BE, et al. The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin: Cholesterol acyltransferase. Diabetologia 2007;50:643-653.
7. Nobecourt E, Zeng J, Davies MJ, et al. Effects of cross-link breakers, glycation inhibitors and insulin sensitizers on HDL function and the non-enzymatic glycation of apolipoprotein A-I. Diabetologia 2008;51:1008-1017.
8. Duell PB, Oram JF, Bierman EL. Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes 1991;40:377-384.
9. Gillotte KL, Davidson WS, Lund-Katz S, Rothblat GH, Phillips MC. Apolipoprotein A-I structural modification and the functionality of reconstituted high density lipoprotein particles in cellular cholesterol efflux. J Biol Chem 1996;271:23792-23798.
10. Passarelli M, Tang C, McDonald TO, et al. Advanced glycation end product precursors impair ABCA1-dependent cholesterol removal from cells. Diabetes 2005;54:2198-2205.
11. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: The Framingham Study. Circulation 1979;59:8-13.
12. Wang N, Silver DL, Costet P, Tall AR. Specific binding of Apo A-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J Biol Chem 2000;275:33053-33058.
13. Liadaki KN, Liu T, Xu S, et al. Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I. Effect of lipid association and APOA-I mutations on receptor binding. J Biol Chem 2000;275:21262-21271.
14. Bito R, Shikano T, Kawabata H. Isolation and characterization of denatured serum albumin from rats with endotoxicosis. Biochim Biophys Acta 2003;1646:100-111.
15. Maciejko JJ, Mao SJT. Radioimmunoassay of apolipoprotein A-I. Application of a non-ionic detergent (Tween-20) and solid-phase staphylococcus. Clin Chem 1982;28:199-204.
16. Mooradian AD, Haas MJ, Wong NC. Transcriptional control of Apo A-I expression in diabetes. Diabetes 2004;53:513-520.
17. Billingham MS, Leatherdale BA, Hall RA, Bailey CJ. High density lipoprotein cholesterol and apolipoprotein A-1 concentrations in non-insulin dependent diabetics treated by diet and chlorpropamide. Diabetes Metab 1982;3:229-233.
18. Calvo C, Talussot C, Ponsin G, Berthezene F. Non enzymatic glycation of apolipoprotein A-I. Effects on its self-association and lipid binding properties. Biochem Biophys Res Commun 1988;153:1060-1067.
19. Fournier N, Myara I, Atger V, Moatti N. Reactivity of lecithin-cholesterol acyl transferase (LCAT) toward glycated high-density lipoprotein (HDL). Clin Chim Acta 1995;234:47-61.
20. Nobecourt E, Tabet F, Lambert G, et al. Nonenzymatic glycation impairs the anti-inflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2010;30:766-772.
21. Cassese A, Esposito I, Fiory F, et al. In skeletal muscle advanced glycation end products (AGEs) inhibit insulin action and induce the formation of multimolecular complexes including the receptor for AGEs. J Biol Chem 2008;283:36088-36099.
22. Flory F, Lombardi A, Miele C, Giudicelli J, Bequinot F, Van Obberghen E. Methylglyoxal impairs insulin signaling and insulin action on glucose-induced insulin secretion in the pancreatic beta cell line INS-1E. Diabetologia 2011;54:2941-2952.
23. Reaven GM, Banting L. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
24. Haffner SM. The prediabetic problem: Development of non-insulin-dependent diabetes mellitus and related abnormalities. J Diabetes Complications 1997;11:69-76.